Format

Send to

Choose Destination
Evid Based Complement Alternat Med. 2014;2014:683570. doi: 10.1155/2014/683570. Epub 2014 May 29.

Concurrent Use in Taiwan of Chinese Herbal Medicine Therapies among Hormone Users Aged 55 Years to 79 Years and Its Association with Breast Cancer Risk: A Population-Based Study.

Author information

1
Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Section 2, Linong Street, Beitou District, Taipei City 112, Taiwan ; Department of Chinese Medicine, Taipei City Hospital, Yangming Branch, No. 105, Yusheng Street, Shilin District, Taipei City 111, Taiwan.
2
Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Section 2, Linong Street, Beitou District, Taipei City 112, Taiwan ; Department of Chinese Medicine, Taipei City Hospital, Yangming Branch, No. 105, Yusheng Street, Shilin District, Taipei City 111, Taiwan ; Taiwan Association for Traditional Chinese Medicine of Family, 9F., No. 105, Yusheng Street, Shilin District, Taipei City 111, Taiwan.
3
Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Section 2, Linong Street, Beitou District, Taipei City 112, Taiwan ; Taiwan Association for Traditional Chinese Medicine of Family, 9F., No. 105, Yusheng Street, Shilin District, Taipei City 111, Taiwan.
4
Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Section 2, Linong Street, Beitou District, Taipei City 112, Taiwan ; Department of Chinese Medicine, Taipei City Hospital, Renai Branch, No. 10, Section 4, Ren'ai Road, Da'an District, Taipei City 106, Taiwan.

Abstract

BACKGROUND:

The purpose of the present study was to analyze the concurrent use of Chinese herbal products (CHPs) among women aged 55 to 79 years who had also been prescribed hormonal therapies (HT) and its association with breast cancer risk.

METHODS:

The use, frequency of service, and CHP prescribed among 17,583 HT users were evaluated from a random sample of 1 million beneficiaries from the National Health Insurance Research Database. A logistic regression method was used to identify the factors that were associated with the coprescription of a CHP and HT. Cox proportional hazards regressions were performed to calculate the hazard ratios (HRs) of breast cancer between the TCM nonusers and women who had undergone coadministration of HT and a CHP or CHPs.

RESULTS:

More than one out of every five study subjects used a CHP concurrently with HT (CHTCHP patients). Shu-Jing-Huo-Xie-Tang was the most commonly used CHP coadministered with HT. In comparison to HT-alone users, the HRs for invasive breast cancer among CHTCHP patients were not significantly increased either in E-alone group or in mixed regimen group.

CONCLUSIONS:

The coadministration of hormone regimen and CHPs did not increase the risk of breast cancer.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center